Overexpression of LncRNA PSMG3-AS1 Distinguishes Glioblastomas from Sarcoidosis
- PDF / 1,194,517 Bytes
- 5 Pages / 595.276 x 790.866 pts Page_size
- 4 Downloads / 172 Views
Overexpression of LncRNA PSMG3-AS1 Distinguishes Glioblastomas from Sarcoidosis Liusheng Chen 1 & Guanliang Wang 2
&
Zihui Xu 3 & Kailong Lin 2 & Sen Mu 1 & Yicheng Pan 2 & Mengya Shan 3
Received: 19 February 2020 / Accepted: 19 May 2020 # Springer Science+Business Media, LLC, part of Springer Nature 2020
Abstract In clinical practices, glioblastomas (GBM) in some cases can be misdiagnosed as sarcoidosis. This study aimed to develop a biomarker to distinguish GBM from sarcoidosis. In this study, we found that PSMG3-AS1 was upregulated in plasma of GBM patients in comparison with that in sarcoidosis patients and healthy controls. Receiver operating characteristic (ROC) curve analysis showed that upregulation of PSMG3-AS1 effectively separated GBM patients from sarcoidosis patients and healthy controls. In GBM cells, overexpression of PSMG3-AS1 led to downregulated miR-34a and increased methylation of miR-34a gene. In addition, overexpression of PSMG3-AS1 reduced the inhibitory effects of miR-34a on GBM cell proliferation. In conclusion, overexpression of PSMG3-AS1 distinguishes GBM patients from patients with sarcoidosis, and PSMG3-AS1 may promote GBM cell proliferation by downregulating miR-34a through methylation. Keywords Glioblastomas . Sarcoidosis . PSMG3-AS1 . miR-34a . Methylation
Introduction Glioblastoma (GBM), as a common type of brain tumor, is a grade IV glioma (Weller et al. 2015). Due to the site of its origin and advanced clinical stage, GBM causes an unacceptable high mortality rate (Mulpur et al. 2015). It is estimated that the median survival time of GBM patients is only about 16 months after the initial diagnosis, and only 5% GBM patients can survive for more than 5 years even after active treatment (Delgado-López and Corrales-García 2016; Ostrom et al. 2018). Even worse, GBM in some cases can be easily misdiagnosed as other brain diseases, Electronic supplementary material The online version of this article (https://doi.org/10.1007/s12031-020-01605-9) contains supplementary material, which is available to authorized users. * Guanliang Wang [email protected] 1
75th Army Military Medical Research Center, Dali, Yunnan Province 671003, People’s Republic of China
2
Department of Traditional Chinese Medical Rehabilitation, 75th Army Military Hospital, Dali, Yunnan Province 671003, People’s Republic of China
3
Department of Traditional Chinese Medicine, Second Affiliated Hospital of Army Military Medical University, Chongqing City 400037, People’s Republic of China
such as sarcoidosis, leading to even worse overall survival (Huang et al. 2019; Traber et al. 2015). Therefore, accurate diagnosis of GBM is still critical to improve the survival of GBM. Previous studies have developed a considerable number of diagnostic markers for GBM (Nicolaidis 2015; Szopa et al. 2017). These markers include EGFR mutation/amplification, MGMT promotor methylation, IDH1/IDH2 mutation, and imaging characteristics (Nicolaidis 2015; Szopa et al. 2017). However, these makers are either limited by the low accuracy or th
Data Loading...
